ClinicalTrials.gg

Program

FHND-9041

A development code. Also written as “FHND9041”.

In Sino Biopharmaceutical's pipeline, EGFR抑制剂 (第三代). Its studies are mostly in Carcinoma, Non-Small-Cell Lung, led by Sino Biopharmaceutical.

Furthest: phase 3, since Dec 23, 20241 company-led study, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sino Biopharmaceutical11 open or runningphase 3since Dec 23, 2024Dec 23, 2024none ahead
  • Named in Sino Biopharmaceutical’s own pipeline as FHND9041, phase 4, as of Nov 16, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 23, 2024First study: phase 3 study in Carcinoma, Non-Small-Cell LungFirst studyNCT06759857 · 350 planned · China

TargetBeta

“EGFR抑制剂 (第三代)”the company's pipeline, read by Claude · source

Other programs on EGFR

ProgramCompanyFurthest phaseStudies
izalontamab brengitecanSichuan Biokin Pharmaceuticalphase 355
pimurutamabFosun Pharmaphase 317
Anti-EGFR Antibody-drug Conjugate CPO301CSPC Pharmaceutical Groupphase 316
sunvozertinibruleDizal Pharmaceuticalsphase 312
becotatugCSPC Pharmaceutical Groupphase 311
andamertinibruleavistone-biotechnology-co-ltdphase 310
becotatug vedotinrulelepu-biopharma-co-ltdphase 310
sevabertinibruleBayerphase 38
HS-10504Hansoh Pharmaceutical Groupphase 37
befotertinibruleBetta Pharmaceuticalsphase 36
petosemtamabruleGenmabphase 36
bafisontamabruleshanghai-epimab-biotherapeutics-co-ltdphase 35

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06759857Carcinoma, Non-Small-Cell Lung · China3By invitationMar 4, 2025350

How it is read

Names in the registry

  • “FHND9041”, 1 entry

Codes read as this program: FHND9041.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.